ОСЕЛЬТАМИВИР — СРЕДСТВО ПРОТИВОВИРУСНОЙ ТЕРАПИИ ГРИППА A(H1N1)pdm09 У ДЕТЕЙ И ВЗРОСЛЫХ

Л. В. Осидак,В В Зарубаев, О. И. Афанасьева,Любовь Васильевна Волощук,В. В. Гончар,М. М. Писарева,Е. Г. Головачева,Е А Дондурей,В. С. Афанасьева,В. Ф. Суховецкая,Е В Образцова, Е. В. Рожкова,А. А. Го, В. М. Гусева,А. А. Штро, Н. Ю. Каика

CHILDREN INFECTIONS（2016）

Cited 3|Views23

No score

Abstract

In this article are presented the results of comparative of experimental (on cell cultures) study of the influenza virus strains sensitivity to neuraminidase inhibitor — Oseltamivir and blocker of M-canal — Rimantadin аnd the results of study effectiveness of the inclusion in the complex therapy of 331 hospitalized patients (children and adults) rapy of А(Н1N1)pdm09 antiviral drug — inhibitor of neuraminidase Oseltamivir that occurred during the epidemic seasons 2009—2010 and 2015—2016 in terms of observational clinical studies. It is shown that this drug, can be successfully used in the treatment of children and adults with influenza А(Н1N1)pdm09 during 8—9 years after beginning of pandemic cycle.

Translated text

Key words

antiviral therapy,influenza

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined